Z Radical Contains Carbon To Carbon Unsaturation Patents (Class 514/549)
-
Patent number: 9468620Abstract: The present invention relates to use of DHA analogs and their pharmaceutical compositions for treating ototoxicity, by administering these compounds or pharmaceutical compositions to subjects in need thereof. Ototoxicity is defined as damage to the structures of the ear, such as the cochlea and vestibular system, by drugs or toxins. Ototoxicity can result in irreversible hearing loss, tinnitus, dysequilibrium, Meniere's disease, or vertigo.Type: GrantFiled: February 26, 2014Date of Patent: October 18, 2016Assignee: Andida Pharma, Inc.Inventor: Per Gjorstrup
-
Patent number: 9446013Abstract: Embodiments of the invention comprise methods of reducing circulating oxidized low density lipoprotein-beta-2-glycoprotein 1 and circulating Myeloperoxidase levels by administering to subjects an effective amount of a dietary oil composition containing 20-90 wt % polyunsaturated fatty acids. Lowering oxidized low density lipoprotein-beta-2-glycoprotein complex and Myeloperoxidase levels may be an effective treatment of atherosclerosis.Type: GrantFiled: November 10, 2009Date of Patent: September 20, 2016Inventor: Bomi Patel Framroze
-
Patent number: 9447020Abstract: There are provided compounds of formula (I): wherein X1 is O, NH, or S; X2 is O, NH, or S; and X3 is O, NH, or S; and wherein R, R1, T1 and T2 can represent various entities. Such compounds can be useful, for example, for preventing, palliating or treating various diseases such as heart diseases, respiratory diseases, treating inflammatory abnormalities, metabolic disorders or diabetes.Type: GrantFiled: October 28, 2014Date of Patent: September 20, 2016Assignee: SCF PHARMA INC.Inventor: Samuel C. Fortin
-
Patent number: 9416118Abstract: The invention describes novel mono or dihydroxy docosahexaenoic acid (DHA) analogs, their preparation, isolation, identification, purification and uses thereof.Type: GrantFiled: June 8, 2012Date of Patent: August 16, 2016Assignee: The Brigham and Women's Hospital, Inc.Inventors: Charles N. Serhan, Rong Yang
-
Patent number: 9364454Abstract: The invention describes novel isolated, purified, 10,17-dihydroxy-docosahexaenoic acids, esters, derivatives and their preparation.Type: GrantFiled: September 24, 2012Date of Patent: June 14, 2016Assignees: The Brigham and Women's Hospital, Inc., University of Southern CaliforniaInventors: Charles N. Serhan, Nicos A. Petasis, Bruce D. Levy
-
Patent number: 9358293Abstract: A method of treating neurological condition in a subject by administration of a cardiac glycoside is provided. Alzheimer's disease, Huntington's disease or stroke are treated by administering a therapeutically effective amount of cardiac glycoside to a subject. The cardiac glycoside can be present in a dosage form.Type: GrantFiled: June 4, 2013Date of Patent: June 7, 2016Assignee: Phoenix Biotechnology, Inc.Inventors: Otis C. Addington, Robert A. Newman
-
Patent number: 9326507Abstract: A composition and method for treating a Varroa mite infestation using a sexual pheromone for disrupting the mating behavior of the Varroa mite. Additionally, a pesticide for applying to a mating place of the Varroa mite for disrupting the mating behavior of the Varroa mite.Type: GrantFiled: August 6, 2013Date of Patent: May 3, 2016Assignee: Universitaet HohenheimInventors: Bettina Ziegelmann, Peter Rosenkranz
-
Patent number: 9265745Abstract: The present invention relates to the use of an acid enriched in docosahexaenoic acid (DHA) or eicosapentaenoic acid (EPA) or DHA-derived EPA for manufacturing a drug for the treatment of processes that involve associated oxidative damage. In particular, it is for the treatment of processes associated with neurodegenerative, ocular, ischaemic and inflammatory pathology, atherosclerosis, with oxidative damage to DNA and with physical exercise.Type: GrantFiled: December 20, 2006Date of Patent: February 23, 2016Assignee: Brudy Technology S.L.Inventors: Joan Carles Domingo Pedrol, Jose Antonio Villegas Garcia
-
Patent number: 9259408Abstract: The present invention relates to the use of an acid enriched in docosahexaenoic acid (DHA) or eicosapentaenoic acid (EPA) or DHA-derived EPA for manufacturing a drug for the treatment of processes that involve associated oxidative damage. In particular, it is for the treatment of processes associated with neurodegenerative, ocular, ischaemic and inflammatory pathology, atherosclerosis, with oxidative damage to DNA and with physical exercise.Type: GrantFiled: March 14, 2013Date of Patent: February 16, 2016Assignee: Brudy Technology S.L.Inventors: Joan Carles Domingo Pedrol, Jose Antonio Villegas Garcia
-
Patent number: 9220778Abstract: A method of treating neurological condition in a subject by administration of a cardiac glycoside is provided. Alzheimer's disease, Huntington's disease or stroke are treated by administering a therapeutically effective amount of cardiac glycoside to a subject. The cardiac glycoside can be present in a dosage form.Type: GrantFiled: June 4, 2013Date of Patent: December 29, 2015Assignee: Phoenix Biotechnology, Inc.Inventors: Otis C. Addington, Robert A. Newman
-
Patent number: 9132112Abstract: A pharmaceutical formulation comprising at least one omega-3 polyunsaturated fatty acid in free acid form or a pharmacologically acceptable derivative thereof is contained in a soft gelatin capsule characterized in that the capsule comprises gelatin extracted by an extraction process comprising acid pre-treatment of a collagen source. One advantage of the present invention over a soft gelatin capsule containing the same formulation but comprising gelatin extracted by an extraction process comprising alkali pre-treatment of the collagen source is that the present invention does not harden significantly over time and thus has a longer shelf life.Type: GrantFiled: April 22, 2014Date of Patent: September 15, 2015Assignee: CHYSALIS PHARMA AGInventors: Jean-Pierre Sachetto, Roly Bufton, Thomas Buser
-
Patent number: 9089483Abstract: This invention provides a self-emulsifying composition comprising 50 to 95% by weight in total of at least one compound selected from the group consisting of ?3 polyunsaturated fatty acids and their pharmaceutically acceptable salts and esters; and 5 to 50% by weight of an emulsifier having a hydrophilic lipophilic balance of at least 10. The composition has no or reduced ethanol content, and exhibits excellent self-emulsifying property, dispersibility in the composition, emulsion stability, and absorption property. The composition is adapted for use as a drug.Type: GrantFiled: November 1, 2013Date of Patent: July 28, 2015Assignee: MOCHIDA PHARMACEUTICAL CO., LTD.Inventors: Hirosato Fujii, Motoo Yamagata
-
Publication number: 20150141510Abstract: The present invention provides the following: a cardiovascular disease primary prevention agent, which comprises as the active ingredient at least one selected from the group consisting of EPA, salts thereof, and esters thereof and is for lowering the risk of cardiovascular disease by administration to subjects having a blood (serum or plasma) hs-CRP level of 1.0 mg/L or higher in spite of no history of cardiovascular disease; a combination marker comprising the blood hs-CRP value and serum EPA/AA ratio for evaluating the primary risk of cardiovascular disease in subjects having no history of cardiovascular disease; and a method for extracting subjects with high risk of cardiovascular disease and/or a method for preventing cardiovascular disease.Type: ApplicationFiled: May 14, 2013Publication date: May 21, 2015Applicants: KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION, MOCHIDA PHARMACEUTICAL CO., LTD.Inventors: Yutaka Kiyohara, Toshiharu Ninomiya, Takashi Yano
-
Patent number: 9034923Abstract: The present invention relates to the treatment of Senile Dementia of the Alzheimer's Type (SDAT) by administering to the patient and effective amount of 1-alkyl, 2-acyl-glycerol.Type: GrantFiled: August 27, 2007Date of Patent: May 19, 2015Assignee: Phenomenome Discoveries Inc.Inventor: Dayan Burke Goodenowe
-
Publication number: 20150133408Abstract: The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of fibromyalgia, restless leg syndrome may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of motor neurone disease, diabetic neuropathy, postherpetic neuralgia, acute opioid withdrawal management, obsessive-compulsive disorder, premature ejaculation, PTSD, injury, post-operative pain, osteoarthritis, rheumatoid arthritis, multiple sclerosis, spinal cord injury, migraine, HIV related neuropathic pain, bipolar depression, depression, stress, cancer pain and lower back pain.Type: ApplicationFiled: February 16, 2013Publication date: May 14, 2015Inventor: Mahesh KANDULA
-
Publication number: 20150132389Abstract: Described herein are compositions including at least one Omega-3 fatty acid ester and at least one surface active agent; wherein the compositions form micelles when in contact with an aqueous medium. Also provided is a method of administering to a subject a composition comprising at least one Omega-3 fatty acid ester and at least one surface active agent, wherein the at least one Omega-3 fatty acid ester forms micelles when in contact with an aqueous medium, and the bioavailability of the at least one Omega-3 fatty acid ester is substantially independent of a food effect. Said compositions are useful for treating cardiovascular conditions or disorders in a subject and for reducing side effects associated with the ingestion of Omega-3 fatty acid esters. Described are also various dosage forms for administering said compositions and use of said compositions in functional foods. Provided herein are also kits with instructions on how to administer said compositions.Type: ApplicationFiled: December 22, 2014Publication date: May 14, 2015Inventors: Frederick Sancilio, Peter Persicaner, Janice Cacace, Mohand Dahim
-
Publication number: 20150125529Abstract: Described herein are compositions including at least one Omega-3 fatty acid ester and at least one surface active agent; wherein the compositions form micelles when in contact with an aqueous medium. Also provided is a method of administering to a subject a composition comprising at least one Omega-3 fatty acid ester and at least one surface active agent, wherein the at least one Omega-3 fatty acid ester forms micelles when in contact with an aqueous medium, and the bioavailability of the at least one Omega-3 fatty acid ester is substantially independent of a food effect. Said compositions are useful for treating cardiovascular conditions or disorders in a subject and for reducing side effects associated with the ingestion of Omega-3 fatty acid esters. Described are also various dosage forms for administering said compositions and use of said compositions in functional foods. Provided herein are also kits with instructions on how to administer said compositions.Type: ApplicationFiled: December 22, 2014Publication date: May 7, 2015Inventors: Frederick Sancilio, Peter Persicaner, Janice Cacace, Mohand Dahim
-
Publication number: 20150126601Abstract: Liquid compositions comprising suspended, solid insect growth regulators are disclosed. Processes for producing such liquid compositions and uses thereof in animal feeds are also disclosed.Type: ApplicationFiled: May 10, 2013Publication date: May 7, 2015Inventor: Bruce Moechnig
-
Publication number: 20150125530Abstract: Described herein are compositions including at least one Omega-3 fatty acid ester and at least one surface active agent; wherein the compositions form micelles when in contact with an aqueous medium. Also provided is a method of administering to a subject a composition comprising at least one Omega-3 fatty acid ester and at least one surface active agent, wherein the at least one Omega-3 fatty acid ester forms micelles when in contact with an aqueous medium, and the bioavailability of the at least one Omega-3 fatty acid ester is substantially independent of a food effect. Said compositions are useful for treating cardiovascular conditions or disorders in a subject and for reducing side effects associated with the ingestion of Omega-3 fatty acid esters. Described are also various dosage forms for administering said compositions and use of said compositions in functional foods. Provided herein are also kits with instructions on how to administer said compositions.Type: ApplicationFiled: December 22, 2014Publication date: May 7, 2015Inventors: Frederick Sancilio, Peter Persicaner, Janice Cacace, Mohand Dahim
-
Publication number: 20150119423Abstract: The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of local pain may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of moderate to severe pain, neuropathic pain, post herpetic neuralgia and rheumatic pains.Type: ApplicationFiled: May 18, 2013Publication date: April 30, 2015Inventor: Mahesh Kandula
-
Publication number: 20150119462Abstract: The invention describes novel 14-hydroxy docosahexaenoic acid (DHA) analogues, their preparation, isolation, identification, purification and uses thereof.Type: ApplicationFiled: December 1, 2014Publication date: April 30, 2015Inventors: Charles N. SERHAN, Rong YANG
-
Publication number: 20150111749Abstract: Methods and compositions for controlling plant pests, particularly weeds and/or plant phytopathogens using sarmentine and/or analogs thereof are disclosed.Type: ApplicationFiled: December 31, 2014Publication date: April 23, 2015Inventors: Huazhang Huang, Ratnakar Asolkar
-
Publication number: 20150111966Abstract: The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of fibromyalgia pain may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of injury, post-operative pain, osteoarthritis, rheumatoid arthritis, multiple sclerosis, spinal cord injury, migraine, HIV related neuropathic pain, post herpetic neuralgia, diabetic neuropathy, bipolar depression, stress, cancer pain, and lower back pain.Type: ApplicationFiled: February 10, 2013Publication date: April 23, 2015Inventor: Mahesh KANDULA
-
Patent number: 9012501Abstract: A pharmaceutical formulation comprising at least one omega-3 polyunsaturated fatty acid in free acid form or a pharmacologically acceptable derivative thereof is contained in a soft gelatin capsule characterized in that the capsule comprises gelatin extracted by an extraction process comprising acid pre-treatment of a collagen source. One advantage of the present invention over a soft to gelatin capsule containing the same formulation but comprising gelatin extracted by an extraction process comprising alkali pre-treatment of the collagen source is that the present invention does not harden significantly over time and thus has a longer shelf life.Type: GrantFiled: January 4, 2013Date of Patent: April 21, 2015Assignee: Chrysalis Pharma AGInventors: Jean-Pierre Sachetto, Roly Bufton, Thomas Buser
-
Publication number: 20150104403Abstract: Provided are polyglyceryl compositions comprising one or more polyglyceryl compounds having: (a) a node structure comprising at least three contiguous glyceryl remnant units; (b) one or more cationic groups each linked to the node structure by an independently selected linking group; and (c) one or more hydrophobic moieties each independently (i) linked to the node structure by a linking group, or (ii) constituting a portion of one of the one or more cationic groups, wherein the composition has an average degree of polymerization determined by hydroxyl value testing (DPOH) of from about 3 to about 20. Also provided are polyglyceryl compounds which may compose such compositions, and uses of the polyglyceryl compositions and compounds.Type: ApplicationFiled: December 18, 2014Publication date: April 16, 2015Inventors: Michael J. Fevola, Frank C. Sun, Stacey E. York
-
Publication number: 20150104402Abstract: Provided are polyglyceryl compositions comprising one or more polyglyceryl compounds having: (a) a node structure comprising at least three contiguous glyceryl remnant units; (b) one or more cationic groups each linked to the node structure by an independently selected linking group; and (c) one or more hydrophobic moieties each independently (i) linked to the node structure by a linking group, or (ii) constituting a portion of one of the one or more cationic groups, wherein the composition has an average degree of polymerization determined by hydroxyl value testing (DPOH) of from about 3 to about 20. Also provided are polyglyceryl compounds which may compose such compositions, and uses of the polyglyceryl compositions and compounds.Type: ApplicationFiled: December 18, 2014Publication date: April 16, 2015Inventors: Michael J. Fevola, Frank C. Sun, Stacey E. York
-
Patent number: 9006285Abstract: Disclosed is a novel therapeutic means against interferon-resistant hepatitis C. Specifically disclosed are: a pharmaceutical composition for treating interferon-resistant hepatitis C, which is characterized by comprising at least one component selected from the group consisting of an ?-3 polyunsaturated fatty acid, a pharmaceutically acceptable salt of the fatty acid and an ester of the fatty acid as an active ingredient; and a method for utilizing the pharmaceutical composition.Type: GrantFiled: September 30, 2009Date of Patent: April 14, 2015Assignee: Mochida Pharmaceutical Co., Ltd.Inventor: Haruo Ohnishi
-
Patent number: 9000039Abstract: The present invention relates generally to the field of lipids and in particular aims at improving lipid absorption, for example under conditions of lipid maldigestion or malabsorption. One embodiment of the present invention relates to a composition comprising sn-1(3) monoacylglycerols, wherein the sn-1 or sn-3 position is occupied by an acyl group such as a fatty acid and the sn-2 position remains unoccupied. The fatty acid may be one with anti-inflammatory properties.Type: GrantFiled: April 3, 2012Date of Patent: April 7, 2015Assignee: Nestec S.A.Inventors: Frederic Destaillats, Cristina Cruz-Hernandez, Fabiola Dionisi, Isabelle Masserey-Elmelegy, Manuel Oliveira, Julie Moulin
-
Patent number: 8993623Abstract: The present invention relates to a method of lowering cholesterol in a patient in need thereof by administering to said patient a therapeutic effective amount of a compound selected from the group of Dihydroxyacetone phosphate (DHAP); 1-acyl-DHAP; 1-alkyl-DHAP; 1-alkyl-glyceraldehyde-3-phosphate (G3P); 1-alkyl, 2-acyl-G3P; 1-alkyl, 2-acyl-glycerol; 1-alkyl,2-acyl-glycerylphosphatidylethanolamine (GPE), 1-alkyl, diacyl glycerol (sn-1=16:0, sn-2=docosohexaenoic acid (DHA); sn-3=DHA) (sn-1 position has an alkyl ether bond, sn-2 and sn-3 positions have acyl bonds); 1-alkyl diacyl glycerol (sn-1=16:0, sn-2=18:1, sn-3=18:1) (sn-1 position has an alkyl ether bond, sn-2 and sn-3 positions have acyl bonds); triacyl glycerol (sn-1=16:0, sn-2=DHA, sn-3=DHA) (all three positions have acyl bonds); and triacyl glycerol (sn-1=16:0, sn-2=18:1, sn-3=18:1) (all three positions have acyl bonds) and pharmaceutically acceptable salts thereof.Type: GrantFiled: June 18, 2012Date of Patent: March 31, 2015Assignee: Phenomenome Discoveries Inc.Inventor: Dayan Burke Goodenowe
-
Publication number: 20150087697Abstract: The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I; and methods for treating or preventing muscle pain, a neurological disease, allergy, respiratory diseases or inflammatory disorder may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of muscle disorders, muscle pain, spasticity, neuropathic pain, fibromyalgia, Parkinson's disease, allergy, chronic obstructive pulmonary disease, allergic rhinitis, headache, chronic pain, sub-chronic pain and local pain or its associated complications.Type: ApplicationFiled: January 25, 2013Publication date: March 26, 2015Inventor: Mahesh KANDULA
-
Patent number: 8987486Abstract: An object of the present invention is to provide a novel trans-2-decenoic acid derivative or a pharmaceutically acceptable salt thereof and to provide a pharmaceutical agent which contains said compound as an active ingredient and has a highly safe neurotrophic factor-like activity or an alleviating action for side effect induced by administration of anti-cancer agents. The trans-2-decenoic acid derivative or a pharmaceutically acceptable salt thereof which is the compound of the present invention is specifically represented by the formula (1): (In the formula, Y is —O—, —NR— or —S—, R is hydrogen atom, alkyl group, dialkylaminoalkyl group or the like and W is a substituent such as dialkylaminoalkyl group) and has a quite high usefulness as a pharmaceutical agent such as a preventive or therapeutic agent for dementia, Alzheimer's disease, Parkinson's disease, depression, etc., a treating or repairing agent for spinal cord injury.Type: GrantFiled: November 1, 2011Date of Patent: March 24, 2015Assignees: Nagoya Industrial Science Research Institute, Nippon Zoki Pharmaceutical Co., Ltd.Inventors: Munekazu Iinuma, Shoei Furukawa, Mitsuru Naiki, Tomonori Matsumoto, Hachiro Sugimoto
-
Patent number: 8987329Abstract: A composition which is adapted for oral consumption and which is in the form of a substantially homogeneous aqueous emulsion, suspension or dispersion comprising salicylic acid, or a C1 to C6 alkyl ester thereof, and docosahexaenoic acid (DHA) can exhibit an anti-inflammatory effect in skin.Type: GrantFiled: April 5, 2007Date of Patent: March 24, 2015Assignee: Conopco, Inc.Inventors: John Casey, Alexander Gordon James, Gail Jenkins, Linda Jane Wainwright
-
Patent number: 8986665Abstract: Provided are polyglyceryl compositions comprising one or more polyglyceryl compounds having: (a) a node structure comprising at least three contiguous glyceryl remnant units; (b) one or more cationic groups each linked to the node structure by an independently selected linking group; and (c) one or more hydrophobic moieties each independently (i) linked to the node structure by a linking group, or (ii) constituting a portion of one of the one or more cationic groups, wherein the composition has an average degree of polymerization determined by hydroxyl value testing (DPOH) of from about 3 to about 20. Also provided are polyglyceryl compounds which may compose such compositions, and uses of the polyglyceryl compositions and compounds.Type: GrantFiled: December 20, 2011Date of Patent: March 24, 2015Assignee: Johnson & Johnson Consumer Companies, Inc.Inventors: Michael J. Fevola, Frank C. Sun, Stacey E. York
-
Patent number: 8986722Abstract: It is an object of the present invention to provide a pest control composition capable of exerting a high effect on pests such as spider mites and aphids even at low concentration using a food/food additive with high safety to the human body and the environment. The present inventors have intensively studied to solve the above problem and found that, among polyglycerol fatty acid esters widely used as a food additive, a composition containing a polyglycerol fatty acid ester which has an HLB of 5 or less and is liquid at ordinary temperature and also a nonionic surfactant has a high effect on pests even at low concentration, and that the possibility for pests to develop resistance to the composition is extremely low, and the present invention has been completed.Type: GrantFiled: February 22, 2011Date of Patent: March 24, 2015Assignee: Nippon Kayaku Kabushiki KaishaInventors: Takeshi Suzuki, Takaaki Miyake, Kazuteru Ogawa
-
Patent number: 8980949Abstract: The present invention provides a use of a lipid composition for the preparation of a nutritional, pharmaceutical or nutraceutical composition or a functional food, for the prevention and treatment of gastrointestinal diseases and disorders, and for promoting intestinal development, maturation, adaptation and differentiation.Type: GrantFiled: December 20, 2013Date of Patent: March 17, 2015Assignee: Enzymotec Ltd.Inventors: Fabiana Bar-Yosef, Gai Ben Dror, Tzafra Cohen, Yael Lifshitz
-
Publication number: 20150073050Abstract: In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of reducing triglycerides in a subject on omeprazole therapy, the method comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.Type: ApplicationFiled: September 9, 2014Publication date: March 12, 2015Inventor: Joseph S. Zakrzewski
-
Publication number: 20150065572Abstract: In various embodiments, the present invention provides methods of treating and/or preventing prostate cancer and, in particular, the method comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.Type: ApplicationFiled: September 4, 2014Publication date: March 5, 2015Inventor: Joseph S. Zakrzewski
-
Publication number: 20150057347Abstract: The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II; and methods for treating or preventing inflammation and lipid disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of hypertriglyceridemia, steatohepatitis, cystinosis and inflammatory diseases.Type: ApplicationFiled: November 5, 2014Publication date: February 26, 2015Inventor: Mahesh Kandula
-
Publication number: 20150057348Abstract: There are provided methods for treating an inflammatory diseases chosen from inflammatory bowel diseases, asthma, acute respiratory distress syndrome, chronic obstructive pulmonary disease, acute lung injury, bronchopulmonary dysplasia, cystic fibrosis, bronchitis, bronchiolitis, arthritis, osteoarthritis, ankylosing spondylitis and rheumatism. The method comprise administering to a subject in need thereof an effective amount of at least one lipid and an effective amount of at least one compound chosen from compounds of the present disclosure. Such compounds are polyunsaturated fatty acid monoglycerides or derivatives thereof.Type: ApplicationFiled: November 5, 2014Publication date: February 26, 2015Inventor: Samuel FORTIN
-
Publication number: 20150051282Abstract: In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of reducing triglycerides in a subject on glucosamine therapy, the method comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.Type: ApplicationFiled: August 12, 2014Publication date: February 19, 2015Inventor: Joseph S. Zakrzewski
-
Publication number: 20150051143Abstract: The disclosure provides for a method for treating a fatty liver disorder in a subject in need thereof, comprising selecting a subject having or suspected of having a fatty liver disease or disorder, wherein the subject is non diabetic, pre-diabetic, mildly diabetic, or has normal or substantially normal biliary tract function; and administering a therapeutically effective amount of a pharmaceutical composition comprising ethyl eicosapentanoate (EPA-E). In some cases EPA-E present may be at least 40% by weight in total of the fatty acids and their derivatives.Type: ApplicationFiled: March 13, 2014Publication date: February 19, 2015Applicant: Mochida Pharmaceutical Co., LTDInventors: Tsuyoshi Harada, Hideo Kanehiro, Kiyoshi Mizuguchi
-
Publication number: 20150045431Abstract: In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of reducing triglycerides in a subject on Apo-C3 modulating therapy, the method comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.Type: ApplicationFiled: August 6, 2014Publication date: February 12, 2015Inventor: Joseph S. Zakrzewski
-
Patent number: 8952055Abstract: The present invention provides a pharmaceutical composition that has excellent safety and targets a different step in the virus propagation cycle than conventional pharmaceutical compositions, applicable as an antiviral agent. A pharmaceutical composition containing an epigallocatechin gallate derivative represented by the following chemical formula (1), an isomer thereof, or a salt thereof is prepared. This can be used as a membrane fusion inhibitor that inhibits viral membrane fusion. In the following formula, R1 to R6 are each a hydrogen atom, halogen, sodium, potassium, or a straight-chain or branched, saturated or unsaturated acyl group and may be identical to or different from one another. The acyl group may be substituted further with one or more substituents. At least one of R1 to R6 is the acyl group. R7 to R16 are each a hydrogen atom, halogen, sodium, or potassium and may be identical to or different from one another.Type: GrantFiled: February 2, 2009Date of Patent: February 10, 2015Assignee: Protectea, Ltd.Inventors: Kunihiro Kaihatsu, Shuichi Mori, Tomo Daidoji, Nobuo Kato, Shinya Miyake
-
Publication number: 20150037306Abstract: The present invention relates to a method for controlling insects comprising the steps of preparing a tankmix by mixing a larvicide and a liquid adjuvant, wherein the adjuvant is essentially free of the larvicide and contains at least 1 wt % polyorganosiloxane, and at least 20 wt % synthetic organic solvent; and applying the tankmix on a water surface. The invention further relates to a liquid adjuvant for preparing a larvicidal tankmix, wherein the adjuvant is essentially free of a larvicide and contains at least 1 wt % polyorganosiloxane, and at least 20 wt % synthetic organic solvent. Finally, it relates to a method for preparing said adjuvant, comprising mixing the polyorganosiloxan and the synthetic organic solvent.Type: ApplicationFiled: January 21, 2013Publication date: February 5, 2015Applicant: BASF SEInventors: Claude Taranta, Helmut Mueller, Susanne Stutz, Egon Weinmueller, James W. Austin
-
Patent number: 8933126Abstract: Mixture of fatty acids, their derivatives, ester or methyl ester derivates thereof, which may be administered to non-human mammals by diffusion in to ambient air during at least seven consecutive days, with a rapid kinetic of diffusion during the first three days of administration.Type: GrantFiled: May 29, 2009Date of Patent: January 13, 2015Assignee: Ceva Sante AnimaleInventors: Benedicte Deminiere, Sandrine Lacoste, Marie-Laure Loubiere
-
Publication number: 20150011631Abstract: An anti-inflammatory composition for treatment of inflamed joints. This composition includes an alkali buffered creatine and a cetylated fatty acid. The composition can be used for treating inflammation either by oral ingestion or by topical treatment.Type: ApplicationFiled: May 20, 2014Publication date: January 8, 2015Inventor: Jeffrey M. Golini
-
Patent number: 8921421Abstract: The invention relates to an inhibitor of dimethylarginine dimethylaminohydrolase (DDAH) of general structural formula (I), wherein B is a branched or unbranched, substituted or non-substituted, saturated or unsaturated hydrocarbon chain having a chain length of 1 to 6 and/or a substituted or non-substituted aromatic system having a ring size of 3 to 6; R1 is selected from the group of structures (i-vii), wherein R2, R3 and R4 are selected from the group consisting of hydrogen, an alkyl or aryl radical, R5 and R6 are selected from the group consisting of hydrogen, a hydrocarbon chain having a chain length of 1 to 8 and an aryl radical, R7, R8, R9 and R10 are selected from the group consisting of hydrogen, and alkyl or aryl radical; W is oxygen (O) or nitrogen (N); and X is a methylene group (CH2) or a secondary amino group (NH); Y is a branched or unbranched, substituted or non-substituted, saturated or unsaturated hydrocarbon chain having a chain length of 1 to 6 and/or a substituted or non-substituted aromatType: GrantFiled: December 8, 2009Date of Patent: December 30, 2014Assignee: Christian-Albrechts-Universitaet Zu KielInventors: Bernd Clement, Jürke Kotthaus, Dennis Schade
-
Publication number: 20140378543Abstract: Methods for producing a composition that includes an active agent, nutraceutical and pharmaceuticals compositions, and methods for ameliorating and/or treating a disease using the composition that includes an active substance are described herein. More particularly, methods for producing a composition that contains one or more active substances such as oleocanthal, pharmaceutical compositions that include one or more active substances such as oleocanthal, and methods of ameliorating and/or treating inflammation using compositions that contains one or more active substances such as oleocanthal are described.Type: ApplicationFiled: September 11, 2014Publication date: December 25, 2014Inventor: Erwin Denk
-
Publication number: 20140371312Abstract: Disclosed is a composition which is useful for preventing the occurrence of a cardiovascular event, particularly a composition which is expected to show a prophylactic effect on a cardiovascular event occurring in a hypercholesterolemia patient despite providing the patient with a treatment with HMG-CoA RI or a cardiovascular event occurring in a multiple risk patient.Type: ApplicationFiled: September 2, 2014Publication date: December 18, 2014Inventors: Mitsuhiro YOKOYAMA, Hideki ORIGASA, Masunori MATSUZAKI, Yuji MATSUZAWA, Yasushi SAITO
-
Publication number: 20140364416Abstract: One embodiment described herein is related to methods and compositions, such as nutraceutical formulations and dietary supplements, comprising C16:1n7-palmitoleate or derivatives thereof. The methods and compositions comprising C16:1n7-palmitoleate, or derivatives thereof, safely and effectively prevent or mitigate manifestations of cardiovascular disease, including coronary artery disease and the accumulation of cholesterol or lipid deposits in the blood vessels of a subject.Type: ApplicationFiled: April 1, 2014Publication date: December 11, 2014Applicant: Tersus Pharmaceuticals, LLCInventor: Jeffrey Green